
Ilse Schwarzinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1557254/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discovery, 2022, 12, 372-387.	9.4	77
2	Attenuation of canonical NFâ€₽B signaling maintains function and stability of human Treg. FEBS Journal, 2021, 288, 640-662.	4.7	9
3	Adequate scattergram interpretation increases the reliability of automated polymorphonuclear (pmn) cell counts from ascitic fluid of patients with liver cirrhosis. International Journal of Laboratory Hematology, 2021, 43, 0176-0180.	1.3	0
4	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. Neoplasia, 2021, 23, 1183-1191.	5.3	1
5	NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML. Blood, 2021, 138, 3435-3435.	1.4	1
6	Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response. Annals of Hematology, 2020, 99, 2599-2609.	1.8	4
7	Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients. Npj Vaccines, 2020, 5, 67.	6.0	8
8	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients. International Journal of Molecular Sciences, 2020, 21, 3025.	4.1	11
9	The TGFâ€b/SOX4 axis and ROSâ€driven autophagy coâ€mediate CD39 expression in regulatory Tâ€cells. FASEB Journal, 2020, 34, 8367-8384.	0.5	28
10	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. Blood, 2020, 136, 2-4.	1.4	1
11	Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro. Frontiers in Immunology, 2019, 10, 1790.	4.8	12
12	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML). Wiener Klinische Wochenschrift, 2019, 131, 410-418.	1.9	18
13	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. United European Gastroenterology Journal, 2019, 7, 651-661.	3.8	7
14	Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes. Blood, 2019, 134, 4269-4269.	1.4	0
15	Increased lymphocyte cell size with blastoid morphology associated with splenic rupture following cessation of ibrutinib. British Journal of Haematology, 2018, 181, 431-431.	2.5	3
16	Major response of PNH to an AML chemotherapy protocol. Annals of Hematology, 2018, 97, 1487-1488.	1.8	1
17	The <scp>JAK</scp> 2 blocker <scp>TG</scp> 101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia. British Journal of Haematology, 2018, 181, 137-139.	2.5	3
18	Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer. Thrombosis and Haemostasis, 2018, 118, 1875-1884.	3.4	38

ILSE SCHWARZINGER

#	Article	IF	CITATIONS
19	Impaired efferocytosis by monocytes in multiple myeloma. Oncology Letters, 2018, 16, 409-416.	1.8	9
20	Mortality in patients resuscitated from out-of-hospital cardiac arrest based on automated blood cell count and neutrophil lymphocyte ratio at admission. Resuscitation, 2017, 116, 49-55.	3.0	37
21	Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm. Wiener Klinische Wochenschrift, 2017, 129, 404-410.	1.9	4
22	<i>In vitro</i> and <i>in vivo</i> effects of <scp>JAK</scp> 2 inhibition in chronic myelomonocytic leukemia. European Journal of Haematology, 2016, 97, 562-567.	2.2	13
23	Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?. Haematologica, 2016, 101, e492-e492.	3.5	1
24	Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation. Blood, 2016, 128, 3189-3189.	1.4	0
25	High Spontaneous In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia is Associated with Mutations in Rasopathy Genes, Myeloproliferation and Inferior Prognosis. Blood, 2016, 128, 5503-5503.	1.4	0
26	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. PLoS ONE, 2014, 9, e111440.	2.5	64
27	FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. Leukemia Research Reports, 2014, 3, 8-13.	0.4	12
28	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. Blood, 2014, 124, 2859-2859.	1.4	3
29	Lysis matters: Red cell lysis with FACS Lyse affects the flow cytometric enumeration of circulating leukemic blasts. Journal of Immunological Methods, 2013, 390, 127-132.	1.4	19
30	Performance Evaluation of the Sysmex XE-5000 Hematology Analyzer for White Blood Cell Analysis in Cerebrospinal Fluid. Archives of Pathology and Laboratory Medicine, 2012, 136, 194-198.	2.5	29
31	Prognostic Significance of Serial Determinations of LDH Levels in Primary (De Novo) Myelodysplastic Syndromes Blood, 2006, 108, 4828-4828.	1.4	0
32	The Paternally Expressed Gene 10 (PEG10) on Chromosome 7q21 Is Overexpressed and Imprinted in High-Risk B-CLL Blood, 2005, 106, 1221-1221.	1.4	0